Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of
A regimen of Roche's Tecentriq and Avastin has become the first immunotherapy-based combination to reduce the risk of liver cancer returning after surgery to remove the tumour in a phase 3
Drugmaker AstraZeneca has teamed up with Indian digital health specialist Qure.ai and a clinical group in the UK to test an artificial intelligence-powered technology to help radiologists d
Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-sta
New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical "game changer